EG017
Phase 2Small molecule
Changchun GeneScience Pharmaceutical Co., Ltd.EG017 is one of 39 small molecule programs targeting Stress urinary incontinence. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Prolia
AmgenPreclinical
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
EG017
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 2
Feraheme
AAzurity Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Systemic Treatment
TTaproot Health
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EG017. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details